Showing results (61-70 of 92) with videos related to

Sort By:
Pageof 10
Nature Communications|March 18, 2020
Chromatin accessibility promotes hematopoietic and leukemia stem cell activityLucia Cabal-Hierro, Peter van Galen, Miguel A Prado, et al.
Cell Reports|January 5, 2022
AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemiaAdrien Grenier, Laury Poulain, Johanna Mondesir, et al.
Blood|June 28, 2019
Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmarkJustin Taylor, Michael Haddadin, Vivek A Upadhyay, et al.
Leukemia & Lymphoma|March 15, 2022
Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclaxEvan C Chen, Yiwen Liu, Courtney E Harris, et al.
Blood|July 7, 2026
Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell NeoplasmAndrew A Lane, Marlise R Luskin, Julia H Keating, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 15, 2023
Cutaneous Manifestations of Myeloid Neoplasms Exhibit Broad and Divergent Morphologic and Immunophenotypic Features but Share Ancestral Clonal Mutations With Bone MarrowSam Sadigh, Daniel J DeAngelo, Jacqueline S Garcia, et al.
Cancer Discovery|May 16, 2012
Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantationOliver Weigert, Nadja Kopp, Andrew A Lane, et al.
The Lancet. Oncology|February 29, 2024
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 studyNaval G Daver, Pau Montesinos, Daniel J DeAngelo, et al.
Cell Reports|November 15, 2018
Trisomy of a Down Syndrome Critical Region Globally Amplifies Transcription via HMGN1 OverexpressionCody T Mowery, Jaime M Reyes, Lucia Cabal-Hierro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2026
Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and DecitabineEvan C Chen, Yiwen Liu, Hayden L Bell, et al.
Pageof 10